Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd is a Swiss biopharmaceutical company whose depositary receipt is listed on NASDAQ under the symbol ADXN. The company focuses on discovering, developing, and commercializing small-molecule medicines for neurological disorders, with research centered on G-protein coupled receptors and enzymes. Its pipeline includes Dipraglurant, which is being studied in phase 1 for post-stroke and traumatic brain injury recovery, as well as for Parkinson’s disease levodopa-induced dyskinesia. Addex also develops ADX71149, an orally active mGlu2 positive allosteric modulator, and a GABAB PAM program aimed at conditions such as pain, anxiety, addiction, cough, and overactive bladder. The company has collaboration and licensing arrangements with Janssen Pharmaceuticals and Indivior PLC to support development efforts in related CNS areas. Founded in 2002 and based in Geneva, Switzerland, Addex Therapeutics was formerly known as Addex Pharmaceuticals Ltd.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ADXN
|
$4.96
|
41.7% Upside
|
Undervalued
|
Not available
|
Not available
|
Weak
|
0.0%
|
September 23, 2026
|
0.8x
|
25.1x
|
3.316 M
|
2.391 M
|
3.7%
|
81.3%
|
-246.1
|
33.0%
|
